{
  "id": "602738ac1cb411341a0000d7",
  "type": "list",
  "question": "Which drugs are included in the CABENUVA pill?",
  "ideal_answer": "Cabenuva contains cabotegravir and rilpivirine. It is used for treatment of HIV.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33176247",
    "http://www.ncbi.nlm.nih.gov/pubmed/33872258",
    "http://www.ncbi.nlm.nih.gov/pubmed/32461114",
    "http://www.ncbi.nlm.nih.gov/pubmed/34408543",
    "http://www.ncbi.nlm.nih.gov/pubmed/32495274"
  ],
  "snippets": [
    {
      "text": "Cabenuva\u2122 is recently approved by Health Canada containing LA cabotegravir+LA rilpivirine nanocrystals (ViiV healthcare) for once monthly administration by intramuscular route. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32461114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA\u2122) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32495274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The clinical phase III trials of FLAIR and ATLAS, showed two-drug injectable cabotegravir (CAB) and rilpivirine (RPV) formulation is potent, safe, and tolerable in HIV-infected patients. The recent approval of cabenuva (CAB+RPV) by Health Canada is a milestone in the development of long-term therapies for HIV infection. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33176247",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA\u2122) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Bas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32495274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The approval of the novel long-acting HIV injection; Cabenuva\u00ae- Cabotegravir and Rilpivirine injectable formulation) and the recent call by the World Health Organization for promoting community-based ART management, underscore the remarkable progress towards meeting the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets by 2030. As t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34408543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabenuva-an injectable formulation of cabotegravir and rilpivirine and the first injectable complete therapy for adults with HIV-1-is now approved.It is administered once a month as two intramuscular injections following a month of treatment with the oral forms of these drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33872258",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cabenuva\u2122 is recently approved by Health Canada containing LA cabotegravir+LA rilpivirine nanocrystals (ViiV healthcare) for once monthly administration by intramuscular route.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32461114",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The approval of the novel long-acting HIV injection; Cabenuva\u00ae- Cabotegravir and Rilpivirine injectable formulation) and the recent call by the World Health Organization for promoting community-based ART management, underscore the remarkable progress towards meeting the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets by 2030.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34408543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent approval of cabenuva (CAB+RPV) by Health Canada is a milestone in the development of long-term therapies for HIV infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33176247",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "cabotegravir, rilpivirine"
}